CD274 and neoplasm: Combining biomimetic BPQD-mediated PTT with anti-PD-L1 immunotherapy prevents tumor recurrence and metastasis by converting the tumor microenvironment into an immune-active microenvironment, which strengthens both the local and systemic anticancer immune response.